ClinVar Miner

Submissions for variant NM_000258.2(MYL3):c.184G>A (p.Asp62Asn) (rs730880954)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000158939 SCV000208874 likely pathogenic not provided 2014-04-18 criteria provided, single submitter clinical testing The D62N variant has not been published as a mutation, nor has it been reported as a benign polymorphism to our knowledge. The D62N variant was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The D62N variant is a semi-conservative amino acid substitution, which may impact secondary protein structure as these residues differ in some properties. This substitution occurs at a position that is conserved across species. In silico analysis predicts this variant is probably damaging to the protein structure/function. Missense mutations in nearby residues (E56G, A57G) have been reported in association with HCM, supporting the functional importance of this region of the protein.Therefore, based on the currently available information, it is unclear whether this variant is a pathogenic mutation or a rare benign variant. The variant is found in HCM panel(s).
Laboratory for Molecular Medicine, Partners HealthCare Personalized Medicine RCV000214205 SCV000272076 uncertain significance not specified 2015-06-25 criteria provided, single submitter clinical testing The p.Asp62Asn variant in MYL3 has not been previously published in individuals with cardiomyopathy, but has been reported by 1 laboratory in ClinVar (http://ww w.ncbi.nlm.nih.gov/clinvar/variation/181438) and has been identified in 1/66674 European chromosomes by the Exome Aggregation Consortium (http://exac.broadinsti tute.org). Computational prediction tools and conservation analyses suggest this variant may impact the protein, though this information is not predictive enoug h to determine pathogenicity. In summary, the clinical significance of the p.Asp 62Asn variant is uncertain.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.